In vivo membrane engineering traps Gd-based MRI contrast agents for detecting microhepatocellular carcinoma.

Area of Science:

• Biomedical Engineering
• Molecular Imaging
• Nanotechnology

Background:

• Accurate detection of microhepatocellular carcinoma (HCC) is challenging due to limitations in current imaging techniques.
• Existing modalities often lack the required specificity and sensitivity for early-stage cancer diagnosis.

Purpose of the Study:

• To develop a novel dual-injection magnetic resonance imaging (MRI) peptidic probe for enhanced micro-HCC detection.
• To achieve in situ signal amplification and molecularly precise imaging through in vivo membrane engineering.

Main Methods:

• Programmable nanoparticles were coassembled with GPC3-targeting ligands, a β sheet-forming motif, DBCO handles, and porphyrin IX.
• Nanoparticles were administered systemically, binding to GPC3-overexpressing tumor membranes and transforming into surface-anchored nanofibrils.
• Azide-modified Gd-DOTA was injected for copper-free click conjugation, enhancing longitudinal relaxivity.

Main Results:

• The dual-injection probe demonstrated high specificity for GPC3-overexpressing tumor membranes.
• A nearly fourfold increase in longitudinal relaxivity was achieved post-conjugation.
• MRI revealed significant T1-weighted signal enhancement and improved tumor-to-liver contrast in preclinical models.

Conclusions:

• The in vivo membrane engineering strategy provides a generalizable platform for receptor-guided molecular imaging.
• This approach holds promise for advancing early cancer detection, particularly for micro-HCC.
• The developed peptidic probe offers a new avenue for improving diagnostic accuracy in oncology.